Eric W Price1, Kimberly J Edwards1, Kathryn E Carnazza1, Sean D Carlin1, Brian M Zeglis2, Michael J Adam3, Chris Orvig4, Jason S Lewis5. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Chemistry, Hunter College and the Ph.D. Program in Chemistry, the Graduate Center of the City University of New York, 413 East 69th Street, New York, NY 10021, United States. 3. TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2A3. 4. Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia, Canada V6T 1Z1. 5. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, United States. Electronic address: lewisj2@mskcc.org.
Abstract
OBJECTIVES: To compare the radiolabeling performance, stability, and practical efficacy of the chelators CHX-A″-DTPA and H4octapa with the therapeutic radiometal (90)Y. METHODS: The bifunctional chelators p-SCN-Bn-H4octapa and p-SCN-Bn-CHX-A″-DTPA were conjugated to the HER2-targeting antibody trastuzumab. The resulting immunoconjugates were radiolabeled with (90)Y to compare radiolabeling efficiency, in vitro and in vivo stability, and in vivo performance in a murine model of ovarian cancer. RESULTS: High radiochemical yields (>95%) were obtained with (90)Y-CHX-A″-DTPA-trastuzumab and (90)Y-octapa-trastuzumab after 15min at room temperature. Both (90)Y-CHX-A″-DTPA-trastuzumab and (90)Y-octapa-trastuzumab exhibited excellent in vitro and in vivo stability. Furthermore, the radioimmunoconjugates displayed high tumoral uptake values (42.3±4.0%ID/g for (90)Y-CHX-A″-DTPA-trastuzumab and 30.1±7.4%ID/g for (90)Y-octapa-trastuzumab at 72h post-injection) in mice bearing HER2-expressing SKOV3 ovarian cancer xenografts. Finally, (90)Y radioimmunotherapy studies performed in tumor-bearing mice demonstrated that (90)Y-CHX-A″-DTPA-trastuzumab and (90)Y-octapa-trastuzumab are equally effective therapeutic agents, as treatment with both radioimmunoconjugates yielded substantially decreased tumor growth compared to controls. CONCLUSIONS: Ultimately, this work demonstrates that the acyclic chelators CHX-A″-DTPA and H4octapa have comparable radiolabeling, stability, and in vivo performance, making them both suitable choices for applications requiring (90)Y.
OBJECTIVES: To compare the radiolabeling performance, stability, and practical efficacy of the chelators CHX-A″-DTPA and H4octapa with the therapeutic radiometal (90)Y. METHODS: The bifunctional chelators p-SCN-Bn-H4octapa and p-SCN-Bn-CHX-A″-DTPA were conjugated to the HER2-targeting antibody trastuzumab. The resulting immunoconjugates were radiolabeled with (90)Y to compare radiolabeling efficiency, in vitro and in vivo stability, and in vivo performance in a murine model of ovarian cancer. RESULTS: High radiochemical yields (>95%) were obtained with (90)Y-CHX-A″-DTPA-trastuzumab and (90)Y-octapa-trastuzumab after 15min at room temperature. Both (90)Y-CHX-A″-DTPA-trastuzumab and (90)Y-octapa-trastuzumab exhibited excellent in vitro and in vivo stability. Furthermore, the radioimmunoconjugates displayed high tumoral uptake values (42.3±4.0%ID/g for (90)Y-CHX-A″-DTPA-trastuzumab and 30.1±7.4%ID/g for (90)Y-octapa-trastuzumab at 72h post-injection) in mice bearing HER2-expressing SKOV3 ovarian cancer xenografts. Finally, (90)Y radioimmunotherapy studies performed in tumor-bearing mice demonstrated that (90)Y-CHX-A″-DTPA-trastuzumab and (90)Y-octapa-trastuzumab are equally effective therapeutic agents, as treatment with both radioimmunoconjugates yielded substantially decreased tumor growth compared to controls. CONCLUSIONS: Ultimately, this work demonstrates that the acyclic chelators CHX-A″-DTPA and H4octapa have comparable radiolabeling, stability, and in vivo performance, making them both suitable choices for applications requiring (90)Y.
Authors: Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Celeste A S Regino; Kayhan Garmestani; Martin W Brechbiel Journal: MAbs Date: 2010-09-01 Impact factor: 5.857
Authors: Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar Journal: Eur J Nucl Med Mol Imaging Date: 2011-03-11 Impact factor: 9.236
Authors: Eric W Price; Jacqueline F Cawthray; Gwendolyn A Bailey; Cara L Ferreira; Eszter Boros; Michael J Adam; Chris Orvig Journal: J Am Chem Soc Date: 2012-05-11 Impact factor: 15.419
Authors: Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis Journal: J Nucl Med Date: 2010-07-21 Impact factor: 10.057
Authors: Stig Palm; Richard M Enmon; Cornelia Matei; Katherine S Kolbert; Su Xu; Pat B Zanzonico; Ronald L Finn; Jason A Koutcher; Steven M Larson; George Sgouros Journal: J Nucl Med Date: 2003-07 Impact factor: 10.057
Authors: Lisa DeFazio-Eli; Kristi Strommen; Trang Dao-Pick; Gordon Parry; Laurie Goodman; John Winslow Journal: Breast Cancer Res Date: 2011-04-15 Impact factor: 6.466
Authors: Lily Li; María de Guadalupe Jaraquemada-Peláez; Eduardo Aluicio-Sarduy; Xiaozhu Wang; Todd E Barnhart; Weibo Cai; Valery Radchenko; Paul Schaffer; Jonathan W Engle; Chris Orvig Journal: Dalton Trans Date: 2020-04-09 Impact factor: 4.390
Authors: Aohan Hu; Ivan Keresztes; Samantha N MacMillan; Yang Yang; Erdong Ding; Warren R Zipfel; Robert A DiStasio; John W Babich; Justin J Wilson Journal: Inorg Chem Date: 2020-03-27 Impact factor: 5.165
Authors: Sai Kiran Sharma; Jonathan M Glaser; Kimberly J Edwards; Elaheh Khozeimeh Sarbisheh; Akam K Salih; Jason S Lewis; Eric W Price Journal: Bioconjug Chem Date: 2020-04-01 Impact factor: 6.069
Authors: Fátima Lucio-Martínez; Zoltán Garda; Balázs Váradi; Ferenc Krisztián Kálmán; David Esteban-Gómez; Éva Tóth; Gyula Tircsó; Carlos Platas-Iglesias Journal: Inorg Chem Date: 2022-03-11 Impact factor: 5.165